
Repligen Investor Relations Material
Latest events

Q1 2025
Repligen
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Repligen Corporation
Access all reports
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process. The company's bioprocessing platforms includes technologies and systems used to develop, manufacture, store, test and distribute biotherapeutic products. It offers a portfolio that is engineered to meet the strict needs of biopharmaceutical manufacturers, and scalable to service the varied needs of manufacturing across the industry. The company sells its products through direct sales force and through applications engineering groups located in North America and Europe. Repligen Corporation is based in Waltham, Massachusetts.
Latest articles
)
Upcoming IPOs to Watch in 2025
Potential IPOs in 2025 include prominent names like Shein, Databricks, Klarna, eToro, and Figma, to name a few. Let's take a closer look.
23 May 2025
)
Figma: Collaborative Design Tool Ready for IPO
Figma, the popular design platform, is preparing for a potential IPO in 2025 as it continues to reshape the future of collaborative design.
22 May 2025
)
Companies That Had Their IPO in 2024: Momentum Increasing
2024 marked a steady year for IPOs, driven by strong markets, AI momentum, and high-profile listings across industries and regions.
22 May 2025
Ticker symbol
RGEN
Country
🇺🇸 United States